This assay was developed by Parker et al. [16], for subclassification of breast cancers into three molecular subtypes [luminal A/B, basal-like (BL) and human epidermal growth factor receptor 2 (Her-2)]. The gene discussed is ERBB2; the disease is breast carcinoma.